News
NICE rejects AZ's Lynparza tablets in ovarian cancer mainten...
AstraZeneca has said it will continue pricing negotiations with the NHS and NICE after the cost-effectiveness body said the tablet formulation of Lynparza (olaparib) is too expensive for re
